1681.HK
Consun Pharmaceutical Group Limited
1681.HK
(3.5)6,16 HKD
15.3% ROA
22.79% ROE
5.25x PER
3.591.485.223,48 HKD
14.63% DER
12.12% Yield
29.77% NPM
Consun Pharmaceutical Group Limited Stock Analysis
Consun Pharmaceutical Group Limited Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
ROE
ROE surpassing expectations (23.7%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect. |
|
| 2 |
ROA
This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors. |
|
| 3 |
PBV
With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price. |
|
| 4 |
DER
The stock has a minimal amount of debt (15%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 5 |
Assets Growth
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance. |
|
| 6 |
Dividend
With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income. |
|
| 7 |
Revenue Growth
This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment. |
|
| 8 |
Net Profit Growth
The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors. |
|
| 9 |
Graham Number
The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option. |
|
| 10 |
Dividend Growth
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice. |
|
| 11 |
Buffet Intrinsic Value
The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value. |
Consun Pharmaceutical Group Limited Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
Consun Pharmaceutical Group Limited Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2012 | 457.801.000 | |
| 2013 | 571.765.000 | 19.93% |
| 2014 | 730.683.000 | 21.75% |
| 2015 | 831.108.000 | 12.08% |
| 2016 | 1.223.488.000 | 32.07% |
| 2017 | 1.660.230.000 | 26.31% |
| 2018 | 1.843.973.000 | 9.96% |
| 2019 | 1.728.256.000 | -6.7% |
| 2020 | 1.752.830.000 | 1.4% |
| 2021 | 2.044.660.000 | 14.27% |
| 2022 | 2.339.650.000 | 12.61% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2012 | 50.721.000 | |
| 2013 | 77.692.000 | 34.72% |
| 2014 | 114.126.000 | 31.92% |
| 2015 | 122.946.000 | 7.17% |
| 2016 | 141.666.000 | 13.21% |
| 2017 | 163.497.000 | 13.35% |
| 2018 | 176.527.000 | 7.38% |
| 2019 | 231.833.000 | 23.86% |
| 2020 | 203.067.000 | -14.17% |
| 2021 | 279.956.000 | 27.46% |
| 2022 | 322.504.000 | 13.19% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2012 | 192.742.000 | |
| 2013 | 219.170.000 | 12.06% |
| 2014 | 251.416.000 | 12.83% |
| 2015 | 335.993.000 | 25.17% |
| 2016 | 446.999.000 | 24.83% |
| 2017 | 627.177.000 | 28.73% |
| 2018 | 715.916.000 | 12.4% |
| 2019 | 246.867.000 | -190% |
| 2020 | 706.539.000 | 65.06% |
| 2021 | 783.745.000 | 9.85% |
| 2022 | 834.899.000 | 6.13% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2012 | 346.689.000 | |
| 2013 | 452.234.000 | 23.34% |
| 2014 | 571.767.000 | 20.91% |
| 2015 | 670.566.000 | 14.73% |
| 2016 | 911.023.000 | 26.39% |
| 2017 | 1.228.395.000 | 25.84% |
| 2018 | 1.384.426.000 | 11.27% |
| 2019 | 1.261.405.000 | -9.75% |
| 2020 | 1.321.671.000 | 4.56% |
| 2021 | 1.527.336.000 | 13.47% |
| 2022 | 1.762.912.000 | 13.36% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2012 | 136.206.000 | |
| 2013 | 152.882.000 | 10.91% |
| 2014 | 211.200.000 | 27.61% |
| 2015 | 249.689.000 | 15.41% |
| 2016 | 307.526.000 | 18.81% |
| 2017 | 396.242.000 | 22.39% |
| 2018 | 465.353.000 | 14.85% |
| 2019 | 63.122.000 | -637.23% |
| 2020 | 498.788.000 | 87.34% |
| 2021 | 590.172.000 | 15.48% |
| 2022 | 682.907.000 | 13.58% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 1 | 0% |
| 2019 | 0 | 0% |
| 2020 | 1 | 0% |
| 2021 | 1 | 0% |
| 2022 | 1 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2012 | 91.498.000 | |
| 2013 | 99.525.000 | 8.07% |
| 2014 | 273.749.000 | 63.64% |
| 2015 | 166.762.000 | -64.16% |
| 2016 | 383.749.000 | 56.54% |
| 2017 | 187.677.000 | -104.47% |
| 2018 | 560.862.000 | 66.54% |
| 2019 | 50.847.250 | -1003.03% |
| 2020 | 813.355.000 | 93.75% |
| 2021 | 627.287.000 | -29.66% |
| 2022 | 896.090.000 | 30% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2012 | 128.832.000 | |
| 2013 | 163.610.000 | 21.26% |
| 2014 | 294.721.000 | 44.49% |
| 2015 | 184.043.000 | -60.14% |
| 2016 | 449.177.000 | 59.03% |
| 2017 | 252.123.000 | -78.16% |
| 2018 | 754.210.000 | 66.57% |
| 2019 | 95.828.750 | -687.04% |
| 2020 | 867.058.000 | 88.95% |
| 2021 | 725.537.000 | -19.51% |
| 2022 | 947.679.000 | 23.44% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2012 | 37.334.000 | |
| 2013 | 64.085.000 | 41.74% |
| 2014 | 20.972.000 | -205.57% |
| 2015 | 17.281.000 | -21.36% |
| 2016 | 65.428.000 | 73.59% |
| 2017 | 64.446.000 | -1.52% |
| 2018 | 193.348.000 | 66.67% |
| 2019 | 44.981.500 | -329.84% |
| 2020 | 53.703.000 | 16.24% |
| 2021 | 98.250.000 | 45.34% |
| 2022 | 51.589.000 | -90.45% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2012 | 355.178.000 | |
| 2013 | 1.257.364.000 | 71.75% |
| 2014 | 1.433.186.000 | 12.27% |
| 2015 | 1.636.755.000 | 12.44% |
| 2016 | 1.760.494.000 | 7.03% |
| 2017 | 1.746.688.000 | -0.79% |
| 2018 | 2.497.012.000 | 30.05% |
| 2019 | 2.306.761.000 | -8.25% |
| 2020 | 2.516.498.000 | 8.33% |
| 2021 | 2.910.781.000 | 13.55% |
| 2022 | 3.439.005.000 | 15.36% |
| 2023 | 3.586.391.000 | 4.11% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2012 | 646.007.000 | |
| 2013 | 1.456.945.000 | 55.66% |
| 2014 | 1.662.941.000 | 12.39% |
| 2015 | 1.917.891.000 | 13.29% |
| 2016 | 2.759.055.000 | 30.49% |
| 2017 | 3.572.017.000 | 22.76% |
| 2018 | 3.897.038.000 | 8.34% |
| 2019 | 3.708.086.000 | -5.1% |
| 2020 | 3.950.253.000 | 6.13% |
| 2021 | 4.362.738.000 | 9.45% |
| 2022 | 4.892.380.000 | 10.83% |
| 2023 | 5.027.374.000 | 2.69% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2012 | 290.829.000 | |
| 2013 | 199.581.000 | -45.72% |
| 2014 | 229.755.000 | 13.13% |
| 2015 | 281.136.000 | 18.28% |
| 2016 | 698.004.000 | 59.72% |
| 2017 | 1.507.869.000 | 53.71% |
| 2018 | 1.400.026.000 | -7.7% |
| 2019 | 1.401.325.000 | 0.09% |
| 2020 | 1.433.755.000 | 2.26% |
| 2021 | 1.451.957.000 | 1.25% |
| 2022 | 1.453.375.000 | 0.1% |
| 2023 | 1.440.983.000 | -0.86% |
Consun Pharmaceutical Group Limited Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 2.96
- Net Income per Share
- 0.86
- Price to Earning Ratio
- 5.25x
- Price To Sales Ratio
- 1.54x
- POCF Ratio
- 3.78
- PFCF Ratio
- 4.01
- Price to Book Ratio
- 1.14
- EV to Sales
- 0.68
- EV Over EBITDA
- 1.92
- EV to Operating CashFlow
- 1.69
- EV to FreeCashFlow
- 1.79
- Earnings Yield
- 0.19
- FreeCashFlow Yield
- 0.25
- Market Cap
- 3,59 Bil.
- Enterprise Value
- 1,60 Bil.
- Graham Number
- 8.79
- Graham NetNet
- 2.18
Income Statement Metrics
- Net Income per Share
- 0.86
- Income Quality
- 1.27
- ROE
- 0.24
- Return On Assets
- 0.15
- Return On Capital Employed
- 0.21
- Net Income per EBT
- 0.9
- EBT Per Ebit
- 1.05
- Ebit per Revenue
- 0.32
- Effective Tax Rate
- 0.1
Margins
- Sales, General, & Administrative to Revenue
- 0.14
- Research & Developement to Revenue
- 0
- Stock Based Compensation to Revenue
- -0
- Gross Profit Margin
- 0.75
- Operating Profit Margin
- 0.32
- Pretax Profit Margin
- 0.33
- Net Profit Margin
- 0.3
Dividends
- Dividend Yield
- 0.12
- Dividend Yield %
- 12.12
- Payout Ratio
- 0.19
- Dividend Per Share
- 0.6
Operating Metrics
- Operating Cashflow per Share
- 1.2
- Free CashFlow per Share
- 1.13
- Capex to Operating CashFlow
- -0.05
- Capex to Revenue
- -0.02
- Capex to Depreciation
- -0.68
- Return on Invested Capital
- 0.19
- Return on Tangible Assets
- 0.15
- Days Sales Outstanding
- 0
- Days Payables Outstanding
- 37.9
- Days of Inventory on Hand
- 174.72
- Receivables Turnover
- 0
- Payables Turnover
- 9.63
- Inventory Turnover
- 2.09
- Capex per Share
- -0.07
Balance Sheet
- Cash per Share
- 3,84
- Book Value per Share
- 3,98
- Tangible Book Value per Share
- 3.81
- Shareholders Equity per Share
- 3.98
- Interest Debt per Share
- 0.6
- Debt to Equity
- 0.15
- Debt to Assets
- 0.09
- Net Debt to EBITDA
- -2.38
- Current Ratio
- 2.68
- Tangible Asset Value
- 3,01 Bil.
- Net Current Asset Value
- 2,17 Bil.
- Invested Capital
- 0.15
- Working Capital
- 2,27 Bil.
- Intangibles to Total Assets
- 0.09
- Average Receivables
- 0,00 Bil.
- Average Payables
- 0,06 Bil.
- Average Inventory
- 259557500
- Debt to Market Cap
- 0.13
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2014 | 0 | |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 1 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
Consun Pharmaceutical Group Limited Profile
About Consun Pharmaceutical Group Limited
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
- CEO
- Mr. Meng An
- Employee
- 3.108
- Address
-
71, Dongpeng Avenue
Guangzhou,
Consun Pharmaceutical Group Limited Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Chi Ming Yau CPA Company Secretary |
70 |
| 2 |
Mr. Meng An Chief Executive Officer & Executive Chairman |
70 |
| 3 |
Lei Zhou Assistant President |
70 |
| 4 |
Mr. Hanxing Xu Assistant GM, Financial Manager & Executive Director |
70 |
| 5 |
Mr. Haien Gao Board Secretary |
70 |
| 6 |
Mr. Guorong Guo Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd |
70 |
| 7 |
Mr. Peicheng Fang Chief Financial Officer & Vice President |
70 |
| 8 |
Ms. Lianhui Chen Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd |
70 |
| 9 |
Prof. Quan Zhu Chief Scientist & Executive Director |
70 |
Consun Pharmaceutical Group Limited Competitors
